You are here: Industry Insights > GlaxoSmithKline

News List

GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019' fiercepharma
December 19, 2018
In the face of "unprecedented" demand for its shingles vaccine, GlaxoSmithKline is doing everything it can to boost supply.
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 18, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
Orchard Therapeutics commits to gene therapies production facility with plans to hire 100 workers fiercepharma
December 14, 2018
Orchard Therapeutics said it intended to use some of the proceeds of an IPO to build a manufacturing facility for its gene therapies program and now it is.
With Advair generics looming, GSK sharpens ax for 650 job cuts fiercepharma
December 12, 2018
After a business review unveiled in July—and ahead of new challenges—GlaxoSmithKline is sharpening its jobs ax to cut 650 across its U.S. business.
GlaxoSmithKline weighs men B shot Bexsero's promise against gonorrhea fiercepharma
December 12, 2018
A study showed meningitis B vaccines like GlaxoSmithKline’s Bexsero can provide some protection against gonorrhea, and now the drugmaker is analyzing whether to move forward with testing in the disease area.
GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019' fiercepharma
December 12, 2018
In the face of "unprecedented" demand for its shingles vaccine, GlaxoSmithKline is doing everything it can to boost supply. But in spite of those efforts—it shipped as much vaccine in the third quarter as it did in the first half of the year—GSK
GlaxoSmithKline weighs Bexsero's promise against gonorrhea fiercepharma
December 11, 2018
A study showed meningitis B vaccines like GlaxoSmithKline’s Bexsero can provide some protection against gonorrhea, and now the drugmaker is analyzing whether to move forward with testing in the disease area.
GlaxoSmithKline taps Unilever as lead bidder in Indian Horlicks buyout: report fiercepharma
December 06, 2018
GlaxoSmithKline has been working to unload its Indian consumer products business, including the nutritional beverage Horlicks, and now the company may be almost there.
GlaxoSmithKline weighs Bexsero's promise against gonorrhea fiercepharma
December 04, 2018
A study showed meningitis B vaccines like GlaxoSmithKline’s Bexsero can provide some protection against gonorrhea, and now the drugmaker is analyzing whether to move forward with testing in the disease area.
GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula firstwordpharma
December 03, 2018
GlaxoSmithKline announced Monday an agreement to acquire Tesaro for around $5.1 billion in cash, gaining the latter's oral PARP inhibitor Zejula (niraparib). GlaxoSmithKline CEO Emma Walmsley said the deal "will strengthen our pharmaceuticals business by

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page